PMC:3724972 / 15665-16250 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/3724972","sourcedb":"PMC","sourceid":"3724972","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3724972","text":"In clinical studies, bromocriptine has had small and variable effects on ACTH secretion in patients with CD [50]. In contrast, a 2004 study demonstrated significant in vitro inhibition of ACTH secretion with cabergoline in 100 % of cases with confirmed D2 receptor expression, and significant in vivo reduction of cortisol levels in 60 % of cases—with 40 % normalization of cortisol secretion [48]. Altogether, 3 small, non-randomized studies (one with a long-term follow-up publication) have found evidence have found evidence for efficacy of cabergoline in this setting [48, 52, 53].","tracks":[{"project":"2_test","denotations":[{"id":"23673515-18642088-63233633","span":{"begin":109,"end":111},"obj":"18642088"},{"id":"23673515-15126577-63233634","span":{"begin":394,"end":396},"obj":"15126577"},{"id":"23673515-15126577-63233635","span":{"begin":573,"end":575},"obj":"15126577"},{"id":"23673515-20497937-63233636","span":{"begin":577,"end":579},"obj":"20497937"},{"id":"23673515-18957500-63233637","span":{"begin":581,"end":583},"obj":"18957500"}],"attributes":[{"subj":"23673515-18642088-63233633","pred":"source","obj":"2_test"},{"subj":"23673515-15126577-63233634","pred":"source","obj":"2_test"},{"subj":"23673515-15126577-63233635","pred":"source","obj":"2_test"},{"subj":"23673515-20497937-63233636","pred":"source","obj":"2_test"},{"subj":"23673515-18957500-63233637","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ece493","default":true}]}]}}